茵冠生物加籍高管接受《深圳日报》专访：深耕生物医药技术，服务人类健康

Chinese-Canadian Zhang Yun is the co-CEO of Shenzhen Wingor Biotechnology Co. Her primary responsibilities include the company’s technology research and development, production preparation, quality management, and product registration and declaration.

华裔加拿大人张芸是深圳市茵冠生物科技有限公司的联席CEO，主要负责技术研发、生产制备、质量管理、产品注册申报、医学相关事务等。

Zhang Yun, co-CEO of Shenzhen Wingor Biotechnology Co., receives an exclusive interview with Shenzhen Daily.

深圳市茵冠生物科技有限公司联席CEO张芸接受英文《深圳日报》专访。

The company, located at Namtai Inno Park in Guangming District, focuses on the whole industry chain ranging from research to the development, transformation and application of cellular and gene therapies.

公司位于光明区的南太云创谷产业园，致力于细胞及基因治疗的研究、开发、转化及应用全产业链的服务。

Zhang completed her undergraduate studies in China, graduating from the Department of Clinical Medicine at the Southeast University School of Medicine. After graduation, she practiced clinical medicine for many years, then went abroad for further studies and received her master’s degree in neuroscience from the University of Saskatchewan in Canada, where she focused on basic medical research related to neural stem cells.

张芸在国内完成了本科学业，毕业于东南大学医学院临床医学系，毕业后从事了多年的临床医疗工作，然后出国留学，在加拿大萨斯卡切温大学获得了神经科学硕士学位，主要开展神经干细胞相关的医学基础研究。

After working abroad in biomedical research for several years, Zhang decided to return to China to focus on the transformation and application of biomedical technologies. In 2013, she joined Wingor to develop cellular and gene therapy drugs, as well as focus on clinical transformation and application research.

在国外从事几年生物医药相关的科研工作后，张芸决定回国专注生物医药技术的转化应用研究，后于2013年加入茵冠生物，开发细胞与基因治疗药物并进行临床转化应用研究。

A researcher of the company conducts some research work.

公司一名研究员在实验室工作。

While she was studying for her master’s degree, Zhang qualified for a national scholarship from Canada for a doctoral degree. However, instead of focusing on basic scientific research, she preferred to combine her clinical work with medical research experience to conduct the transformation and application of advanced medical technologies.

在攻读硕士期间张芸获得了加拿大国家级奖学金名额，可以全额资助直接读博，但因为曾经从事过临床医疗工作，相对于专注在基础科研，她更倾向于结合临床工作和医学科研经验，进行先进医学技术的转化应用。

“After working on biomedical research abroad for a few years, I decided to return to China to focus on the transformation and application of biomedical technologies and to industrialize advanced biomedical technologies for the benefit of human health,” Zhang said.

“在国外从事几年生物医药相关的科研工作后，我决定回国专注生物医药技术的转化应用研究，将先进的生物医药技术进行产业化，服务于人类的健康保障。”张芸说道。

Zhang Yun communicates with a researcher at the lab of the company.

张芸在公司实验室与研究员沟通工作事宜。

Zhang chose Shenzhen because it has been at the forefront of transformational research on stem cell technology worldwide. It’s also the cradle of domestic cell therapy industry.

她选择了深圳，是因为深圳在干细胞技术的转化研究处于全球前列，是国内细胞治疗行业的发源地。

“The 21st century is the era of cellular therapy. In recent years, cellular therapy has demonstrated broad prospects for its application; and the global stem cell industry is developing rapidly with a gradually expanding market on a scale that will reach trillions of yuan in the next three years. Stem cell research and application is the most important segment and has become an important indicator of a country’s life science and medical development, and many countries are strongly supporting the research in this field,” Zhang said.

“21世纪是细胞治疗时代。近年来细胞治疗已经展示了广阔的应用前景，全球细胞行业迅猛发展，市场规模逐渐扩大，未来三年干细胞将会达到万亿级的规模。干细胞研究及应用是最主要的细分领域，成为了衡量一个国家生命科学与医学发展的重要指标，许多国家都对干细胞研究大力支持。”张芸说道。

Based on the rich experience accumulated by their team in stem cell technology research and application over the past 20 years, the company has selected Mesenchymal stem cells (MSCs) as its first-tier stem cell drugs for development. At the same time the company has also developed immune cell and gene editing technologies to provide a sustainable product pipeline of cellular and gene therapies.

基于公司团队近二十年来在干细胞技术研究和转化应用方面积累的丰富经验，他们选择间充质干细胞作为公司第一梯队的干细胞药品进行开发。同时公司也开发了免疫细胞技术及基因编辑技术，为公司提供可持续开发的细胞与基因治疗产品管线。

An exhibition area of the company.

公司的展厅。

“As a leading enterprise in the stem cell industry in Shenzhen, we hope to bring our own unique advantages into play to accelerate the development of stem cell technology industrialization in Shenzhen, and even in the country,” Zhang said.

“作为深圳干细胞行业的领航企业，我们希望能够发挥自身的优势，加快推进深圳、乃至全国干细胞技术产业化的发展及突破。”张芸说。

According to Zhang, Guangming District has provided an excellent platform for the development of enterprises and individuals.

张芸认为，光明区为企业和个人发展都提供了优越的平台。

Zhang Yun works in her office.

张芸在办公室工作。

“Guangming District strongly supports the development of the cellular and gene therapy industry. It took the lead in the country with its release of Measures to Support the Integrated Development of Innovation and Industry Chains of Synthetic Biology, which supports enterprises in this field,” Zhang said.

“光明区非常支持细胞与基因治疗产业的发展，在全国率先发布《支持合成生物创新链产业链融合发展的若干措施》，精准扶持相关产业发展方向的企业。”张芸说。

In terms of attracting and supporting the development of talents, Guangming District released the “Guangming Science City Talent Highland Plan” to build a system of gathering, cultivating and retaining talents through institutional innovation, thus helping the Science City build a gathering place for innovative talents.

在人才扶持方面，光明区出台了”光明科学城人才高地计划”，通过制度创新构建”聚才、育才、留才”的工作体系，助力光明科学城打造创新人才集聚地。

Zhang Yun reads a brochure at the reception of the company.

张芸在公司前台浏览公司宣传册。

Zhang was recognized as a foreign high-level talent of Guangdong Province, a talent of the Shenzhen Peacock Plan and a “Pilot Talent” of Nanshan District in Shenzhen.

张芸被认定为广东省外籍高层次人才、深圳市”孔雀计划”人才以及深圳市南山区”领航人才”。